Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ALEC with free AI briefings, catalyst countdowns, and dilution alerts.

ALEC · Alector, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$138.7M Cash on Hand
14.3mo Cash Runway
Follow ALEC by email Get an email when ALEC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ALEC, unsubscribe in one click. Privacy

📣 What ALEC Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Latozinemab Neurodegenerative Diseases Phase 3 · NCT06111014 Terminated
Part 1 Blinded - AL001 Frontotemporal Dementia Phase 3 · NCT04374136 Terminated
Part 2 (OLE Treatment) - AL001 Frontotemporal Dementia Phase 3 · NCT04374136 Terminated
AL001 Frontotemporal Dementia Phase 2 · NCT03987295 Completed
AL002 Alzheimer's Disease Phase 2 · NCT05744401 Terminated
GSK4527226 Alzheimer's Disease Phase 2 · NCT07105709 Recruiting
AL003 Healthy Phase 1 · NCT03822208 Completed
Osugacestat (AL101) Healthy Phase 1 · NCT04111666 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ALEC holds $138.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $29.2M/quarter from operations, an estimated runway of 14.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 42 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALEC files for a raise →

👥 Who Owns ALEC

Insiders 3.6% Institutions (184 holders) 84% Public and other holders 12.4%
HolderTypeShares% of sharesAs of
Deep Track Capital, LP Institution (13G, 5%+) 12,772,152 8.58% 2026-10-16
BVF PARTNERS L P/IL Institution (13G, 5%+) 9,374,267 6.30% 2026-09-11
RA Capital Management, L.P. Institution (13G, 5%+) 7,500,000 5.04% 2026-10-19
BlackRock, Inc. Institution (13G, 5%+) 5,784,214 3.89% 2026-03-31
Arnon Rosenthal
Chief Executive Officer, Director · +3.92M options
Insider 3,514,600 2.36% 2026-10-13
Sara Kenkare-Mitra
President and Head of R&D · +18,250 options
Insider 501,652 0.34% 2025-12-03
Neil Lindsay Berkley
CFO & Chief Business Officer · +403,000 options
Insider 395,216 0.27% 2026-10-14
Grace Wong-Sarad
Principal Accounting Officer · +219,355 options
Insider 161,570 0.11% 2026-10-13
Louis J Jr Lavigne
Director · +9,450 options
Insider 138,661 0.09% 2026-06-17
Richard H Scheller
Director · +9,450 options
Insider 134,899 0.09% 2026-06-17
Kristine Yaffe
Director · +9,450 options
Insider 124,109 0.08% 2026-06-17
Elizabeth A. Garofalo
Director · +9,450 options
Insider 118,650 0.08% 2026-06-17

Share count 148,877,074 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ALEC picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALEC and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.